BRAF and melanoma: In a phase 2 trial (SECOMBIT) in previously untreated BRAF‐mutated melanoma, patients were randomized to receive niv/ipi as the first line and then switch to enco/bini at disease progression (arm A), enco/bini as the first line and then switch to niv/ipi at disease progression (arm B), or enco/bini and then switch to niv/ipi after 8 weeks of treatment, and enco/bini at disease progression (arm C).